Ignite Creation Date:
2024-05-06 @ 1:02 AM
Last Modification Date:
2024-10-26 @ 10:58 AM
Study NCT ID:
NCT01713426
Status:
COMPLETED
Last Update Posted:
2018-04-23
First Post:
2012-10-22
Brief Title:
A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain PNP After 8 Weeks of Treatment
Sponsor:
Astellas Pharma Europe Ltd
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain an Open-label Randomized Multicenter Non-inferiority Efficacy and Tolerability Study
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ELEVATE
Brief Summary:
This study is comparing the efficacy and tolerability of Qutenza with that of pregabalin in patients suffering from peripheral neuropathic pain Treatment allocation will be to one of these treatments and the duration of the study will be about 10 weeks assuming that from screening to treatment allocation takes 2 weeks Participants will be asked to complete questionnaires about various aspects relating to their condition throughout the study
This study will include subjects suffering from Postherpetic Neuralgia Peripheral Nerve Injury or Non Diabetic peripheral polyneuropathy
This study will include subjects suffering from Postherpetic Neuralgia Peripheral Nerve Injury or Non Diabetic peripheral polyneuropathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-005872-41 | EUDRACT_NUMBER | None | None |